RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy

Conclusions:
RDA is a novel intermediate endpoint that has promise for clinical utility for breast cancers early in response-guided primary systemic therapy.

Source: JNCI Monographs - June 10, 2015 Category: Cancer & Oncology Authors: Pritzker, K., Pritzker, L., Generali, D., Bottini, A., Cappelletti, M. R., Guo, B., Parissenti, A., Trudeau, M. Tags: Article Source Type: research